Preoperative Bevacizumab for Vitreous Hemorrhage

Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab

The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.

Inclusion Criteria:

• Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss lasting more than three months in patients not previously treated and four months in those previously LASER treated.

Exclusion Criteria:

• Previous intra-ocular surgery other than cataract surgery
• Retinal detachment
• Use of anticoagulants drugs other than aspirin
• Vitreous hemorrhage clearance at week-3 study period
• History of previous thromboembolic events